FBLN7 Antibody, Biotin conjugated
-
中文名稱：FBLN7兔多克隆抗體, Biotin偶聯
-
貨號：CSB-PA687502LD01HU
-
規格：￥880
-
其他：
產品詳情
-
產品名稱：Rabbit anti-Homo sapiens (Human) FBLN7 Polyclonal antibody
-
Uniprot No.：
-
基因名：FBLN7
-
別名：FBLN7 antibody; FBLN7_HUMAN antibody; FIBL-7 antibody; Fibl7 antibody; Fibulin-7 antibody; TM14 antibody
-
宿主：Rabbit
-
反應種屬：Human
-
免疫原：Recombinant Human Fibulin-7 protein (25-393AA)
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：Biotin
-
克隆類型：Polyclonal
-
抗體亞型：IgG
-
純化方式：>95%, Protein G purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
產品提供形式：Liquid
-
應用范圍：ELISA
-
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：An adhesion molecule that interacts with extracellular matrix molecules in developing teeth and may play important roles in differentiation and maintenance of odontoblasts as well as in dentin formation.
-
基因功能參考文獻：
- Fbln7-C terminal fragment inhibited the HUVEC tube formation and the vessel sprouting in aortic ring assays. PMID: 24480309
- Dysregulation of fibulin expression by anti-Ro/SSA antibodiess may contribute to disorganization of the extracellular environment and thus cause injury to the salivary gland architecture and functionality observed in Sjogren syndrome PMID: 19229767
-
亞細胞定位：Secreted, extracellular space, extracellular matrix.
-
蛋白家族：Fibulin family
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
